PMI

Picard Medical, Inc.

PMI

Market cap $469M

Overview Fund Activity

6.48 USD

+0.02

0.31%

At close Updated Sep 10, 4:00 PM EDT

Pre-market

After hours

6.53

+0.05

0.77%

1 day

0.31%

5 days

22.03%

1 month

41.18%

3 months

41.18%

6 months

41.18%

Year to date

41.18%

1 year

41.18%

5 years

41.18%

10 years

41.18%

About: Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

Healthcare Medical Instruments & Supplies

–

Funds holding %

of 7,460 funds

–

Analysts bullish %

Financial journalist opinion

Based on 6 articles about PMI published over the past 30 days

Picard Announces Appointment of Two New Members to its Board of Directors

Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership

Picard Announces Appointment of Two New Members to its Board of Directors

Picard Medical, Inc. Announces Exercise of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

TUCSON, Ariz., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that the underwriters of its previously announced initial public offering of common stock, par value $0.0001 per share (the “Common Stock”) have exercised their over-allotment option in full on September 5, 2025, resulting in the issuance of an additional 637,500 shares of Common Stock at a public offering price of $4.00 per share, for gross proceeds of $2,550,000, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC (“NYSE American”) under the ticker symbol “PMI” on August 29, 2025.

Picard Medical, Inc. Announces Exercise of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference

TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel.

Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference

Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering

TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at $4.00 per share (the “Offering”). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwriting discounts, to cover over-allotment, if any. The gross proceeds from the offering were $17 million, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC (“NYSE American”) under the ticker symbol “PMI” on August 29, 2025.

Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering

U.S. IPO Weekly Recap: Quiet Week As IPO Market Gears Up For A Busy Fall

Four small issuers and two SPACs priced offerings in the past week, and a few names joined the pipeline. The largest deals of the week came from the pair of blank check IPOs. There are no IPOs currently scheduled for the short Labor Day week ahead, though we expect to see the first wave of September launches.

U.S. IPO Weekly Recap: Quiet Week As IPO Market Gears Up For A Busy Fall

Picard Medical, Inc. Announces Pricing of $17 Million Initial Public Offering

TUCSON, Ariz., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (“Picard” or the “Company”), a medical technology company that manufactures and sells the only total artificial heart (the “SynCardia Total Artificial Heart”, or “STAH”) approved by the U.S. Food and Drug Administration (“FDA”), and Health Canada, today announced the pricing of its initial public offering (the “Offering”). The Offering consists of 4,250,000 shares of common stock priced at a public offering price of $4.00 per share, for total gross proceeds of $17 million, before deducting underwriting discounts and offering expenses. The shares of common stock have been approved for listing on the NYSE American, LLC and are expected to commence trading on August 29, 2025, under the ticker symbol “PMI.”

Picard Medical, Inc. Announces Pricing of $17 Million Initial Public Offering

Zacks Investment Research

PCE Comes in Warmer Than Expected

PCE Comes in Warmer Than Expected.

PCE Comes in Warmer Than Expected

Zacks Investment Research

Economy Heating Up on PCE for June

Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.

Economy Heating Up on PCE for June

Philip Morris shares fall 7% as Q2 revenue misses

Philip Morris International (PMI), the world's largest tobacco company by market capitalization, reported second-quarter results that fell short of analyst revenue expectations, leading to a 7% drop in its share price during Tuesday's trading session.

Philip Morris shares fall 7% as Q2 revenue misses

Picard Medical Seeks IPO On Dropping Revenue And High Valuation

Picard Medical, Inc. has filed to raise $17 million in an IPO. Management's valuation assumptions are extreme, with the IPO seeking a Price/Sales multiple far above industry norms. Picard faces significant risks, including customer concentration and a lack of long-term contracts.

Picard Medical Seeks IPO On Dropping Revenue And High Valuation

See News Rankings

Charts implemented using Lightweight Charts™